NCT00043355View on ClinicalTrials.gov

Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection

PHASE2TerminatedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2000

Study Completion Date

February 28, 2003

Conditions
Lung Infection
Interventions
DRUG

interferon gamma-1b

500 mcg, oral, three times weekly

Sponsors

Lead Sponsor

InterMune
All Listed Sponsors
lead

InterMune

INDUSTRY

NCT00043355 - Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection | Biotech Hunter | Biotech Hunter